Breaking
🇪🇺 EMA

Latest News

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035
NewsApr 25, 2026

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035

RNA therapy clinical trials market hits $3.4B driven by delivery advances, rare disease funding, and personalized medicine growth through 2035.

Sofia Alvarez
Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline
NewsApr 25, 2026

Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline

Oncotelic Therapeutics provides corporate update on strategic partnerships to advance clinical-stage cancer treatments and expand market reach.

Prof. Marcus Webb
CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026
NewsApr 25, 2026

CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026

CLINUVEL gets final EMA scientific advice for pivotal Phase III vitiligo study comparing SCENESSE with NB-UVB therapy, set to begin second half 2026.

Dr. Amina Farouk
RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results
NewsApr 24, 2026

RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results

RenovoRx announces ASCO acceptance of pharmacokinetic data from Phase III TIGeR-PaC trial testing TAMP therapy platform for pancreatic cancer treatment.

Dr. Amina Farouk
Genomics Services Market to Reach $24 Billion by 2033 as Precision Medicine Adoption Accelerates
NewsApr 24, 2026

Genomics Services Market to Reach $24 Billion by 2033 as Precision Medicine Adoption Accelerates

The global genomics services market is projected to grow at 11.2% CAGR through 2033, driven by precision medicine advances and digital health initiatives.

Dr. Hannah O'Connor
Accenture Invests in Iridius to Accelerate AI Compliance Solutions for Life Sciences Companies
NewsApr 24, 2026

Accenture Invests in Iridius to Accelerate AI Compliance Solutions for Life Sciences Companies

Accenture Ventures invests in Iridius to help pharmaceutical companies adopt compliant AI solutions while maintaining regulatory standards and auditability.

Charlotte Meyer
Pharmaceutical Company Reports Continued Growth Momentum in Q1 2026 Sales Results
NewsApr 24, 2026

Pharmaceutical Company Reports Continued Growth Momentum in Q1 2026 Sales Results

Major pharmaceutical company announces sustained growth in first quarter 2026 sales, maintaining positive momentum from previous periods with investor call scheduled.

Dr. Elena Rossi
Cumberland Pharmaceuticals Announces Strategic Integration with Apotex in Major Commercial Partnership Deal
NewsApr 24, 2026

Cumberland Pharmaceuticals Announces Strategic Integration with Apotex in Major Commercial Partnership Deal

Cumberland Pharmaceuticals (CPIX) enters strategic agreement with Apotex to integrate commercial operations, marking significant shift in specialty pharma landscape.

Prof. Marcus Webb
Reuters Pharma EU: Key Takeaways Day 1
NewsgeneralApr 24, 2026

Reuters Pharma EU: Key Takeaways Day 1

Reuters Events: Pharma EU conference convenes pharmaceutical industry leaders to discuss regulatory developments, market trends, and innovation strategies across European markets. Day 1 establishes key themes and networking opportunities for industry collaboration.

Dr. Elena Rossi
Tilray Brands Positioned for Major U.S. Medical Cannabis Expansion Following Historic Rescheduling
NewsMedical CannabisApr 23, 2026

Tilray Brands Positioned for Major U.S. Medical Cannabis Expansion Following Historic Rescheduling

Tilray Brands leverages international medical cannabis expertise across 20+ countries to capitalize on U.S. market expansion opportunities amid cannabis rescheduling.

Dr. Hannah O'Connor
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
NewsApr 23, 2026

Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access

CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.

Sofia Alvarez
SamaCare Launches Industry-First Prior Authorization Performance Benchmarks for Medical Benefit Drugs
NewsApr 23, 2026

SamaCare Launches Industry-First Prior Authorization Performance Benchmarks for Medical Benefit Drugs

SamaCare introduces first-of-its-kind benchmarks tracking prior authorization approval rates and time to therapy across specialty practices nationwide.

Prof. Marcus Webb
Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors
NewsApr 23, 2026

Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors

Repertoire Immune Medicines begins Phase 1/2 trial of RPTR-1-201, a novel TCR bispecific therapy targeting advanced solid tumors across US and European sites.

Charlotte Meyer
Alpha Tau Treats First Patient with Alpha DaRT in European Pancreatic Cancer Trial ACAPELLA
NewsPancreatic CancerApr 23, 2026

Alpha Tau Treats First Patient with Alpha DaRT in European Pancreatic Cancer Trial ACAPELLA

Alpha Tau initiates Alpha DaRT treatment in ACAPELLA trial for locally advanced pancreatic cancer, addressing unmet need for 42,000 European patients annually.

Dr. Elena Rossi
Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial
NewsApr 23, 2026

Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial

Alpha Tau successfully treats first European patient with Alpha DaRT radiotherapy in French ACAPELLA trial for locally advanced pancreatic cancer.

Sofia Alvarez
Blinatumomab Long-Term Safety Study in Pediatric Leukemia Patients Reaches Final Stage
NewsApr 23, 2026

Blinatumomab Long-Term Safety Study in Pediatric Leukemia Patients Reaches Final Stage

European study evaluating long-term safety of blinatumomab versus chemotherapy in pediatric acute lymphoblastic leukemia patients nears completion.

Dr. Amina Farouk
Healthcare Third-Party Logistics Market to Double by 2034, Reaching $502.6 Billion Driven by Pharmaceutical Growth
NewsApr 23, 2026

Healthcare Third-Party Logistics Market to Double by 2034, Reaching $502.6 Billion Driven by Pharmaceutical Growth

Healthcare 3PL market projected to grow from $246.1B to $502.6B by 2034 at 7.8% CAGR, driven by pharmaceutical expansion and cold chain logistics demand.

Oliver Grant
Pharmaceutical Intermediates Market to Reach $57 Billion by 2035 as Generic Drug Manufacturing Drives 4.5% Annual Growth
NewsApr 23, 2026

Pharmaceutical Intermediates Market to Reach $57 Billion by 2035 as Generic Drug Manufacturing Drives 4.5% Annual Growth

Global pharmaceutical intermediates market projected to grow from $36.62B to $57.03B by 2035, driven by generic drug demand and advanced manufacturing.

Dr. Hannah O'Connor
Reuters Pharma Day 1: Key Takeaways for European Markets
NewsgeneralApr 23, 2026

Reuters Pharma Day 1: Key Takeaways for European Markets

Reuters Events: Pharma Day 1 highlights fragmented European market access strategies, accelerating AI-driven drug development, and evolving regulatory frameworks reshaping the pharmaceutical landscape across the EU.

Dr. Elena Rossi
Reuters Pharma EU: Day 1 Key Takeaways for Pharma Leaders
NewsgeneralApr 23, 2026

Reuters Pharma EU: Day 1 Key Takeaways for Pharma Leaders

Reuters Pharma EU Day 1 coverage requires verified event data and official conference materials to deliver accurate insights. NovaPharmaNews is prepared to provide comprehensive analysis once speaker information, session details, and announced developments are available.

Dr. Elena Rossi